Capital Increase / Dilution2026-07-22

Listing Date Delayed for Capital Increase

UNI

한국유니온제약

080720

+0.05

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2604

Risk-adjusted indicator based on 2604 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Original Listing Date: July 29, 2026
  • • Amended Listing Date: August 5, 2026
  • • Insolvency Plan Approval Date: May 12, 2026
  • • Debt-to-Equity Conversion Effective Date: May 19, 2026
  • • Capital Reduction (Merger) Effective Date: May 27, 2026

AI Analysis Summary

UNION KOREA PHARM CO.,Ltd announced an amendment to its Material Fact Report regarding a paid-in capital increase. The new listing date for the new shares is August 5, 2026, a delay from the original July 29, 2026, due to practical issues with the Korea Securities Depository. This capital increase is part of a court-approved insolvency plan from May 12, 2026, involving debt-to-equity conversion effective May 19, 2026, and capital reduction effective May 27, 2026. The primary purpose is debt repayment through conversion, with no new cash contributions. This will result in a change of the largest shareholder. The amendment itself is a procedural update with minimal direct financial impact.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.